Howard Haspel

Tecan (United Kingdom)

Papers

1

Total Citations

4

H-Index

1

About

Howard Haspel is a scientist whose work has centered on advancing drug development through innovative assay technologies, particularly in the critical area of ADME/Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) screening. His most notable contribution, detailed in his 2003 paper "ADMET Assays on Tecan's LabCD-ADMET System," focused on developing and evaluating three key applications—Cytochrome P450 Inhibition, Serum Protein Binding, and P-glycoprotein Interaction—on a microfluidic platform. This work aimed to streamline the early-stage drug discovery process by enabling faster, more efficient compound screening. While his highly specialized research has accumulated a modest citation count of 4, reflecting its niche application in industrial settings, Haspel's efforts contributed to the practical implementation of lab-on-a-chip technologies for pharmacokinetic profiling. His achievements highlight the importance of bridging cutting-edge microfluidics with real-world pharmaceutical needs, offering valuable insights for researchers interested in assay miniaturization and high-throughput drug screening.

Research Focus

Key Achievements

1
H-Index
1
Papers
4
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
ADMET Assays on Tecan's LabCD-ADMET System
4 citations · 2003
📈 Most Prolific Year: 2003 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Tecan (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago